Nicotine/Opipramol

尼古丁/奥匹哌醇

Report date: 2022/07/04 19:38:02

Base Information

Drug NameNicotine/Opipramol
Drug Alias Name尼古丁和奥匹哌醇Nicotine+Opipramol奥匹哌醇/尼古丁Nicotine-Opipramol尼古丁+奥匹哌醇 +[12] 
ClassificationSmall molecules
Mechanisms of ActionMuscle-type nicotinic acetylcholine receptor agonists
TargetsOpioid receptorsSigma opioid receptorHistamine H1 receptor +[6] 
Therapy Area/IndicationsAttention Deficit Disorder with Hyperactivity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsYes Opipramol HydrochlorideNicotine
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeuroderm Ltd
Active IndicationsN/A
Inactive IndicationsAttention Deficit Disorder with Hyperactivity

Other Information

ATC CodeN/A
Related LinksN/A